Does the media prefer KRYS or NRIX?

In the previous week, Krystal Biotech had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Krystal Biotech and 3 mentions for Nurix Therapeutics. Krystal Biotech's average media sentiment score of 1.32 beat Nurix Therapeutics' score of 1.09 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or NRIX more profitable?

Abivax has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Nurix Therapeutics -928.44% -76.09% -57.31%

Does the media refer more to ABVX or NRIX?

In the previous week, Abivax had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Abivax and 3 mentions for Nurix Therapeutics. Abivax's average media sentiment score of 1.55 beat Nurix Therapeutics' score of 1.09 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or PRAX?

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 3 mentions for Nurix Therapeutics. Praxis Precision Medicines' average media sentiment score of 1.41 beat Nurix Therapeutics' score of 1.09 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.09 beat Kymera Therapeutics' score of 0.95 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or IONS?

In the previous week, Ionis Pharmaceuticals had 24 more articles in the media than Nurix Therapeutics. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.09 beat Ionis Pharmaceuticals' score of 0.34 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 4 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Nurix Therapeutics (NRIX) Competitors

$25.10 -0.71 (-2.75%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$25.12 +0.01 (+0.06%)

As of 09/11/2026 07:30 PM Eastern

Compare

NRIX vs. KRYS, ABVX, PRAX, KYMR, and IONS

Should you buy Nurix Therapeutics stock or one of its competitors? Nurix Therapeutics's main competitors and comparable companies include Krystal Biotech (KRYS), Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nurix Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 54.82% compared to Nurix Therapeutics' net margin of -928.44%. Krystal Biotech's return on equity of 19.34% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Krystal Biotech has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48
Nurix Therapeutics	$36.77M	70.85	-$264.46M	-$3.45	N/A

Krystal Biotech presently has a consensus target price of $365.40, suggesting a potential upside of 5.30%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 36.31%. Given Nurix Therapeutics' higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Krystal Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

In the previous week, Krystal Biotech had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Krystal Biotech and 3 mentions for Nurix Therapeutics. Krystal Biotech's average media sentiment score of 1.32 beat Nurix Therapeutics' score of 1.09 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Nurix Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Nurix Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

47.9% of Abivax shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Abivax presently has a consensus target price of $156.38, suggesting a potential upside of 31.81%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 36.31%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Abivax has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Abivax has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

In the previous week, Abivax had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Abivax and 3 mentions for Nurix Therapeutics. Abivax's average media sentiment score of 1.55 beat Nurix Therapeutics' score of 1.09 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Nurix Therapeutics	$36.77M	70.85	-$264.46M	-$3.45	N/A

Summary

Nurix Therapeutics beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Nurix Therapeutics (NASDAQ:NRIX) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 3 mentions for Nurix Therapeutics. Praxis Precision Medicines' average media sentiment score of 1.41 beat Nurix Therapeutics' score of 1.09 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nurix Therapeutics presently has a consensus price target of $34.21, indicating a potential upside of 36.31%. Praxis Precision Medicines has a consensus price target of $585.95, indicating a potential upside of 75.13%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95

Praxis Precision Medicines has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Praxis Precision Medicines' return on equity of -34.15% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Nurix Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	70.85	-$264.46M	-$3.45	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A

Summary

Praxis Precision Medicines beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Kymera Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Nurix Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	70.85	-$264.46M	-$3.45	N/A
Kymera Therapeutics	$105M	91.04	-$311.35M	-$3.24	N/A

Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 36.31%. Kymera Therapeutics has a consensus target price of $130.83, suggesting a potential upside of 13.81%. Given Nurix Therapeutics' higher probable upside, research analysts clearly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Kymera Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.09 beat Kymera Therapeutics' score of 0.95 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Nurix Therapeutics' net margin of -928.44%. Kymera Therapeutics' return on equity of -21.22% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Summary

Kymera Therapeutics beats Nurix Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Ionis Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, Ionis Pharmaceuticals had 24 more articles in the media than Nurix Therapeutics. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.09 beat Ionis Pharmaceuticals' score of 0.34 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	4 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nurix Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ionis Pharmaceuticals has a net margin of -64.76% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Nurix Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	70.85	-$264.46M	-$3.45	N/A
Ionis Pharmaceuticals	$944M	9.54	-$381.39M	-$3.46	N/A

Nurix Therapeutics currently has a consensus target price of $34.21, indicating a potential upside of 36.31%. Ionis Pharmaceuticals has a consensus target price of $91.25, indicating a potential upside of 68.33%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Nurix Therapeutics beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.68B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-7.28	14.25	275.24	25.29
Price / Sales	70.85	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	4.74	15.12	10.33	6.20
Net Income	-$264.46M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.98%	-4.34%	-3.32%	-2.35%
1 Month Performance	-5.75%	-0.02%	-0.41%	-2.77%
1 Year Performance	177.65%	40.64%	19.21%	7.63%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	2.995 of 5 stars	$25.10 -2.8%	$34.21 +36.3%	+172.8%	$2.68B	$36.77M	N/A	357	Positive News
KRYS Krystal Biotech	3.1574 of 5 stars	$358.24 flat	$365.40 +2.0%	+140.4%	$10.60B	$389.13M	44.89	210	Positive News
ABVX Abivax	2.6108 of 5 stars	$114.79 flat	$156.50 +36.3%	+38.0%	$10.02B	N/A	N/A	61	News Coverage Positive News Analyst Upgrade
PRAX Praxis Precision Medicines	3.0013 of 5 stars	$351.81 flat	$585.95 +66.6%	+748.8%	$9.82B	$8.55M	N/A	110	News Coverage Positive News
KYMR Kymera Therapeutics	1.8089 of 5 stars	$117.39 flat	$128.70 +9.6%	+148.8%	$9.76B	$39.21M	N/A	170	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. KRYS, ABVX, PRAX, KYMR, and IONS

How does Nurix Therapeutics compare to Krystal Biotech?

Summary

How does Nurix Therapeutics compare to Abivax?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Summary

How does Nurix Therapeutics compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. KRYS, ABVX, PRAX, KYMR, and IONS

How does Nurix Therapeutics compare to Krystal Biotech?

Do institutionals & insiders hold more shares of KRYS or NRIX?

Is KRYS or NRIX more profitable?

Which has higher earnings and valuation, KRYS or NRIX?

Do analysts rate KRYS or NRIX?

Which has more volatility & risk, KRYS or NRIX?

Does the media prefer KRYS or NRIX?

Summary

How does Nurix Therapeutics compare to Abivax?

Do institutionals and insiders have more ownership in ABVX or NRIX?

Do analysts rate ABVX or NRIX?

Is ABVX or NRIX more profitable?

Which has more risk and volatility, ABVX or NRIX?

Does the media refer more to ABVX or NRIX?

Which has better valuation and earnings, ABVX or NRIX?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Does the media favor NRIX or PRAX?

Which has more risk and volatility, NRIX or PRAX?

Do institutionals and insiders hold more shares of NRIX or PRAX?

Do analysts recommend NRIX or PRAX?

Is NRIX or PRAX more profitable?

Which has higher valuation and earnings, NRIX or PRAX?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Which has stronger earnings and valuation, NRIX or KYMR?

Do analysts prefer NRIX or KYMR?

Does the media favor NRIX or KYMR?

Which has more risk and volatility, NRIX or KYMR?

Is NRIX or KYMR more profitable?

Summary

How does Nurix Therapeutics compare to Ionis Pharmaceuticals?

Does the media prefer NRIX or IONS?

Which has more risk and volatility, NRIX or IONS?

Do insiders & institutionals believe in NRIX or IONS?

Is NRIX or IONS more profitable?

Which has better valuation and earnings, NRIX or IONS?

Do analysts rate NRIX or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools